Literature DB >> 24619943

The pharmacokinetic study of sinomenine, paeoniflorin and paeonol in rats after oral administration of a herbal product Qingfu Guanjiesu capsule by HPLC.

Ying Xie1, Zhi-Hong Jiang, Hua Zhou, Wen-Zhe Ma, Yuen-Fan Wong, Zhong-Qiu Liu, Liang Liu.   

Abstract

An accurate and reliable high-performance liquid chromatography-diode array detector (HPLC-DAD) method was developed and validated for determination of sinomenine (SI), paeoniflorin (PF) and paeonol (PA), which was further applied to assess the pharmacokinetics of SI, PF and PA in an anti-arthritic herbal product, Qingfu Guanjieshu (QFGJS) capsule, in rats. Successful separation was achieved with a C18 column and a mobile phase composed of acetonitrile and aqueous phase (containing 0.1% formic acid, adjusted with triethylamine to pH 3.5 ± 0.2). The method was validated with excellent precision, accuracy, recovery and stability in calibration ranges from 0.06 to 11.62 µg/mL for SI, from 0.09 to 35.70 µg/mL for PF, and from 0.15 to 4.53 µg/mL for PA (with r(2) > 0.999 for all three compounds). Our results showed that absorption of PF after administration of QFGJS was similar to that after oral administration of PF alone; the absorption of SI was decreased while the absorption of PA was increased after giving QFGJS orally compared with pure compounds. We may conclude that pharmacokinetic studies of complex herbal products are not only necessary but also feasible by using representative bioactive chemicals as indicators of establishing quality control standards and of determining pharmacokinetic behavior of herbal medicines.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HPLC-DAD; herbal product; paeoniflorin; paeonol; pharmacokinetics; sinomenine

Mesh:

Substances:

Year:  2014        PMID: 24619943     DOI: 10.1002/bmc.3165

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Development of Fluorescence-Linked Immunosorbent Assay for Paeoniflorin.

Authors:  Yan Zhao; Huihua Qu; Xueqian Wang; Yue Zhang; Jinjun Cheng; Yan Zhao; Qingguo Wang
Journal:  J Fluoresc       Date:  2015-04-21       Impact factor: 2.217

2.  Comparative pharmacokinetics of four active components on normal and diabetic rats after oral administration of Gandi capsules.

Authors:  Renjie Xu; Jia Qi; Ruan-Juan Zhan; Gui-Sheng Zhou; Bin Hao; Jing Ma; Xin Wei; A-Jing Xu; Jian Zhang
Journal:  RSC Adv       Date:  2018-02-09       Impact factor: 4.036

Review 3.  Beneficial Effects Exerted by Paeonol in the Management of Atherosclerosis.

Authors:  Li Lu; Yating Qin; Chen Chen; Xiaomei Guo
Journal:  Oxid Med Cell Longev       Date:  2018-11-07       Impact factor: 6.543

4.  Pharmacokinetics and Brain Distribution of the Active Components of DA-9805, Saikosaponin A, Paeonol, and Imperatorin in Rats.

Authors:  Mi Hye Kwon; Jin Seok Jeong; Jayoung Ryu; Young Woong Cho; Hee Eun Kang
Journal:  Pharmaceutics       Date:  2018-08-20       Impact factor: 6.321

5.  Comparative pharmacokinetics study of sinomenine in rats after oral administration of sinomenine monomer and Sinomenium acutum extract.

Authors:  Mao-Fan Zhang; Yan Zhao; Kun-Yu Jiang; Long Han; Xiao-Yue Lu; Xin Wang; Lan Zuo; Sheng-Nan Meng
Journal:  Molecules       Date:  2014-08-12       Impact factor: 4.411

6.  An ultra-high performance liquid chromatographic-tandem mass spectrometric method for the determination of sinomenine in human plasma after transdermal delivery of the zhengqing fengtongning injection.

Authors:  Tingbo Chen; Zheng Xiang; Gengting Dong; Pei Luo; Ping Qiu; Shenzhi Wang; Baoming Huang; Yingyi Wen; Feichi Wu; Liang Liu; Hua Zhou
Journal:  Molecules       Date:  2015-04-10       Impact factor: 4.411

7.  The Effect of Acupoint Application of Sinomenine for Rheumatoid Arthritis Measured by Microdialysis and UPLC-MS/MS.

Authors:  Rui Wang; Jing Yang; Yuxuan Liu; Bixi Guan; Qun Feng; Yanhong Wang; Shaowa Lv; Zhixin Yang; Yongji Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.